Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.